Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

BioInvent International AB21 enrolled

Overview

TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented. In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Solid Tumors

Interventions

TB-403BIOLOGICAL

Multiple IV

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed malignity * Measurable disease * Performance status 1 or less (ECOG) Exclusion Criteria: * Acute illness or infection * Concurrent second malignancy

Locations (2)

Onkologisk Klinik 5072 Finsencentret Rigshospitalet

Copenhagen, Denmark

Onkologisk Afdeling 54B1 Herlev Hospital

Herlev, Denmark

Outcomes

Primary Outcomes

Safety and tolerability of an anti-PlGF antibody

Time frame: 85 days

Secondary Outcomes

Determine multiple dose IV pharmacokinetics

Time frame: 85 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.